SeNostic GmbH is a biotechnology company specializing in early diagnosis of neurodegenerative disorders like Alzheimer’s, Parkinson’s, and Amyotrohic Lateral Sclerosis (ALS). Our proprietary SeedCycler® technology detects disease-specific biomarkers years before symptoms appear, offering high sensitivity and specificity. This platform aids in differential diagnosis, patient stratification, and drug discovery by screening therapeutic candidates that target protein aggregation. Our assays target biomarkers such as alpha-synuclein, amyloid-beta, tau, and TDP-43, with applications in clinical diagnostics and preclinical trials. SeNostic’s innovative approach provides crucial tools for the pharma and biotech sectors to develop targeted therapies and enhance clinical outcomes. SeNostic GmbH also produces and distributes high-quality recombinant proteins, essential for research and diagnostic applications, ensuring the reliability and precision of its cutting-edge neurodegenerative disease assays.
Company Details
- Employees
- 15
- Founded
- -
- Address
- Feodor-Lynen Straße, 31,germany
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.senostic.com
- HQ
- Hannover, Lower Saxony
Senostic Gmbh Questions
Senostic Gmbh's website is http://www.senostic.com
Senostic Gmbh's LinkedIn profile is https://de.linkedin.com/company/senostic-gmbh
Senostic Gmbh has
15 employees.
View email and phone details for 15
employees at Senostic Gmbh.
Senostic Gmbh's industry is
Biotechnology Research
Senostic Gmbh's top competitors are
Genetechx,
Centre For Individualised Infection Medicine,
Sysy Antibodies,
Fassisi Gmbh,
Centogene,
Noscendo,
Iba Lifesciences,
Panosome Gmbh,
Sciomics,
Paicon.
Senostic Gmbh's categories are Biotechnology Research
Senostic Gmbh's founding year is 2022
